In Vivo's Rough Guide On The State Of RNAi
How Will RNA Modalities Stack Up Against Gene Therapy?
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. In Vivo reviews the leading drug developers in this space.
You may also be interested in...
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: There was no big M&A, but biopharma CEOs discussed deals they're pursuing. Also, Novartis's Zolgensma reimbursement insights, Sarepta's third DMD filing, Bristol's post-merger progress and more highlights.
The innovative collaboration should accelerate access to the first-in-class cholesterol lowering drug acquired with The Medicines Company buy.
Feature article: Alnylam’s R&D leader Akshay Vaishnaw sets out plans for next-generation gene-silencing therapies.